Paris, France

Danièle Bonnet-Delpon


 

Average Co-Inventor Count = 6.6

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2008-2013

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Danièle Bonnet-Delpon: Innovator in Anti-Cancer and Malaria Treatments

Introduction

Danièle Bonnet-Delpon is a prominent inventor based in Paris, France. He has made significant contributions to the fields of anti-cancer therapy and malaria treatment through his innovative research and development of artemisinin derivatives. With a total of 3 patents, his work has garnered attention in the scientific community.

Latest Patents

One of his latest patents is focused on dimeric derivatives of artemisinin and their application in anti-cancer therapy. This invention relates to dimeric derivatives of 10-trifluoromethylated artemisinin, which are designed to be used in the treatment of cancer. The patent outlines the preparation methods and the various uses of these compounds, particularly in oncology. Another notable patent involves derivatives of artemisinin and their uses in the treatment of malaria. This new class of artemisinin derivatives is aimed at improving therapeutic outcomes for patients suffering from this disease.

Career Highlights

Danièle Bonnet-Delpon has worked with esteemed organizations such as the Centre National de la Recherche Scientifique and Pierre Fabre Medicament. His experience in these institutions has allowed him to advance his research and contribute to significant medical advancements.

Collaborations

Throughout his career, he has collaborated with notable colleagues, including Jean-Pierre Begue and Benoît Crousse. These partnerships have further enriched his research and development efforts.

Conclusion

Danièle Bonnet-Delpon's innovative work in the development of artemisinin derivatives showcases his commitment to addressing critical health challenges such as cancer and malaria. His contributions continue to impact the medical field positively.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…